SCHEMBL4676315

SCHEMBL4676315

Cc1ccccc1CNC(=O)NNC(=O)[C@@H](C)N

nearest known ligand 0.55

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.52
HPGD P15428 3/20 0.52
KDM4E B2RXH2 2/20 0.52
NPC1 O15118 2/20 0.50
RAB9A P51151 2/20 0.50
KMT2A Q03164 3/20 0.49
LMNA P02545 2/20 0.49
GAA P10253 2/20 0.49
MEN1 O00255 2/20 0.49
PKM P14618 1/20 0.49
HTT P42858 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.46
CA2 P00918 1/20 0.45
POLB P06746 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4676041 1.00 ALDH1A1 (0.52) ALDH1A1HPGDKDM4ENPC1RAB9A
SCHEMBL4680873 0.84 NPC1 (0.62) ALDH1A1NPC1RAB9AKMT2AMEN1
SCHEMBL4676212 0.84 SLC1A2 (0.51) ALDH1A1HPGDRAB9AKMT2AMEN1
SCHEMBL4676140 0.84 NPC1 (0.62) ALDH1A1NPC1RAB9AKMT2AMEN1
SCHEMBL4679747 0.84 SLC1A2 (0.51) ALDH1A1HPGDRAB9AKMT2AMEN1
SCHEMBL4677263 0.82 ANPEP (0.58) ALDH1A1HPGDKDM4ENPC1RAB9A
SCHEMBL4681089 0.82 ANPEP (0.58) ALDH1A1KDM4EKMT2AMEN1CA2
SCHEMBL4681194 0.82 ANPEP (0.58) ALDH1A1KDM4EKMT2AMEN1CA2
SCHEMBL4675847 0.82 ANPEP (0.58) ALDH1A1HPGDKDM4ENPC1RAB9A
SCHEMBL4681180 0.81 EPHX2 (0.49) ALDH1A1LMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1633702-B1 PROTEASE INHIBITORS PROZYMEX AS (DK) 2008-07-02 EP claimed
US-20070155803-A1 Protease inhibitors PROZYMEX A/S (DK) 2007-07-05 US claimed
EP-1633702-A1 PROTEASE INHIBITORS Prozymex A/S (DK) 2006-03-15 EP claimed
WO-2004106289-A1 PROTEASE INHIBITORS PROZYMEX A/S (DK) 2004-12-09 WO claimed
EP-1975153-A2 Protease inhibitors Prozymex A/S (DK) 2008-10-01 EP disclosed
EP-1633702-B1 PROTEASE INHIBITORS PROZYMEX AS (DK) 2008-07-02 EP disclosed
US-20070155803-A1 Protease inhibitors PROZYMEX A/S (DK) 2007-07-05 US disclosed
EP-1633702-A1 PROTEASE INHIBITORS Prozymex A/S (DK) 2006-03-15 EP disclosed
WO-2004106289-A1 PROTEASE INHIBITORS PROZYMEX A/S (DK) 2004-12-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070155803-A1 Protease inhibitors DPP7, DPP9, DPP3 ALDH1A1 2713/4885HPGD 4416/4885KDM4E 4185/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.